246 related articles for article (PubMed ID: 21286861)
1. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Li XR; Cheng LQ; Liu M; Zhang YJ; Wang JD; Zhang AL; Song X; Li J; Zheng YQ; Liu L
Med Oncol; 2012 Jun; 29(2):425-31. PubMed ID: 21286861
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
[TBL] [Abstract][Full Text] [Related]
3. Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations.
Bedair R; Priest AN; Patterson AJ; McLean MA; Graves MJ; Manavaki R; Gill AB; Abeyakoon O; Griffiths JR; Gilbert FJ
Eur Radiol; 2017 Jul; 27(7):2726-2736. PubMed ID: 27798751
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response - A Prospective Study.
Pereira NP; Curi C; Osório CABT; Marques EF; Makdissi FB; Pinker K; Bitencourt AGV
Sci Rep; 2019 Nov; 9(1):16372. PubMed ID: 31705004
[TBL] [Abstract][Full Text] [Related]
5. [Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases].
Li XR; Wang JD; Zhang YJ; Kong QL; Ma B; Li J; Zheng YQ; Chen YQ; Jin YC; Li R
Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(2):87-90. PubMed ID: 19489268
[TBL] [Abstract][Full Text] [Related]
6. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Sharma U; Danishad KK; Seenu V; Jagannathan NR
NMR Biomed; 2009 Jan; 22(1):104-13. PubMed ID: 18384182
[TBL] [Abstract][Full Text] [Related]
8. Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.
Galbán CJ; Ma B; Malyarenko D; Pickles MD; Heist K; Henry NL; Schott AF; Neal CH; Hylton NM; Rehemtulla A; Johnson TD; Meyer CR; Chenevert TL; Turnbull LW; Ross BD
PLoS One; 2015; 10(3):e0122151. PubMed ID: 25816249
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of ADC Difference Value on Pre-neoadjuvant Chemotherapy MRI for Response Evaluation of Breast Cancer.
Choi BB
Technol Cancer Res Treat; 2021; 20():15330338211039129. PubMed ID: 34519583
[No Abstract] [Full Text] [Related]
11. Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Dai XL; Han ZB; Yang YT; Qiu J; Liu YF; Feng YZ
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):517-22. PubMed ID: 25907177
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.
Xu HD; Zhang YQ
Neoplasma; 2017; 64(3):430-436. PubMed ID: 28253722
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
Jia Q; Xu J; Jiang W; Zheng M; Wei M; Chen J; Wang L; Huan Y
Int J Med Sci; 2013; 10(2):110-8. PubMed ID: 23329881
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Yu Y; Xiang H; He XM; Yang HJ; Zong XY
Asian Pac J Cancer Prev; 2013; 14(4):2401-6. PubMed ID: 23725148
[TBL] [Abstract][Full Text] [Related]
17. Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Ryoo I; Kim JH; Choi SH; Sohn CH; Kim SC
Magn Reson Med Sci; 2015; 14(4):337-45. PubMed ID: 26104081
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient.
Wu LA; Chang RF; Huang CS; Lu YS; Chen HH; Chen JY; Chang YC
J Magn Reson Imaging; 2015 Nov; 42(5):1407-20. PubMed ID: 25875904
[TBL] [Abstract][Full Text] [Related]
20. [The clinical study on neoadjuvant chemotherapy with combination of docetaxel and pharmorubicin for locally advanced breast cancer].
Li XR; Ma B; Wang JD; Liu HY; Li J; Zheng YQ; Zhang YJ; Chen YQ; Jin YC; Li R
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):85-7. PubMed ID: 18353209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
